CLINICAL TRIALS PROFILE FOR NEXTERONE
✉ Email this page to a colleague
All Clinical Trials for NEXTERONE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | American Heart Association | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | Canadian Institutes of Health Research (CIHR) | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | Defence Research and Development Canada | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | Heart and Stroke Foundation of Canada | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
NCT01401647 ↗ | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2012-05-01 | The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NEXTERONE
Condition Name
Clinical Trial Locations for NEXTERONE
Trials by Country
Clinical Trial Progress for NEXTERONE
Clinical Trial Phase
Clinical Trial Sponsors for NEXTERONE
Sponsor Name